EOX regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of xxx used to treat xxx. ==Regimen== {{chemo|x|xx}} {{chemo|x|xx}}..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | |||
{{PAGENAME}} refers to a regimen consisting of [[epirubicin]], [[oxaliplatin]], [[xeloda|capecitabine (xeloda)]] used to treat advanced oesophagogastric cancer.<ref name="pmid15928658">{{cite journal| author=Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR et al.| title=Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. | journal=Br J Cancer | year= 2005 | volume= 92 | issue= 11 | pages= 1976-83 | pmid=15928658 | doi=10.1038/sj.bjc.6602572 | pmc=PMC2361798 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15928658 }} </ref> | |||
{{PAGENAME}} refers to a regimen consisting of | |||
==Regimen== | ==Regimen== | ||
{{chemo| | {{chemo|E|Epirubicin}} | ||
{{chemo| | {{chemo|O|Oxaliplatin}} | ||
{{chemo| | {{chemo|X|Capecitabine (xeloda)}} | ||
==Indications== | ==Indications== | ||
*[[Oesophageal cancer|Advanced oesophagogastric cancer]]<ref name="pmid15928658">{{cite journal| author=Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR et al.| title=Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. | journal=Br J Cancer | year= 2005 | volume= 92 | issue= 11 | pages= 1976-83 | pmid=15928658 | doi=10.1038/sj.bjc.6602572 | pmc=PMC2361798 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15928658 }} </ref> | |||
Latest revision as of 14:19, 16 March 2015
|
WikiDoc Resources for EOX regimen |
|
Articles |
|---|
|
Most recent articles on EOX regimen Most cited articles on EOX regimen |
|
Media |
|
Powerpoint slides on EOX regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on EOX regimen at Clinical Trials.gov Clinical Trials on EOX regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on EOX regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on EOX regimen Discussion groups on EOX regimen Patient Handouts on EOX regimen Directions to Hospitals Treating EOX regimen Risk calculators and risk factors for EOX regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for EOX regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
EOX regimen refers to a regimen consisting of epirubicin, oxaliplatin, capecitabine (xeloda) used to treat advanced oesophagogastric cancer.[1]
Regimen
EEpirubicin
OOxaliplatin
XCapecitabine (xeloda)
Indications
References
- ↑ 1.0 1.1 Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR; et al. (2005). "Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF". Br J Cancer. 92 (11): 1976–83. doi:10.1038/sj.bjc.6602572. PMC 2361798. PMID 15928658.